Perrigo PRGO
Perrigo Q2 FY26: revenue $1.0B, down 3%; diluted EPS $0.53
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001585364-26-000145
Key figures from this report
These are the numbers Perrigo reported for Q2 FY26, the quarter ended Jun 27, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$1.0B−3% from $1.1B in Q2 FY2510-Q income statement, on EDGAR
- Net income$74.5MAgainst −$8.4M in Q2 FY2510-Q income statement, on EDGAR
- Diluted EPS$0.53Against −$0.06 in Q2 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$399.7M−12% from $454.2M in Q2 FY2510-Q balance sheet, on EDGAR
- Cash from operations$82.6M+9% from $75.9M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Vaxcyte PCVX public float $3.7B, Jun 30, 2025
- Rhythm Pharmaceuticals RYTM public float $3.8B, Jun 30, 2025
- Ultragenyx Pharmaceutical RARE public float $3.4B, Jun 30, 2025
- Avidity Biosciences RNAM public float $3.4B, Jun 30, 2025
- Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025
